Tonn G R, Kwan E, Hall C, Riggs K W, Axelson J E, Rurak D W
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada.
Drug Metab Dispos. 1996 Mar;24(3):273-81.
In this study, two factors that could affect fetal drug exposure were examined: 1) the extent of elimination of drug delivered to the fetal liver from the placenta via the umbilical vein; and 2) the degree to which there is preferential distribution of drug in umbilical venous blood to the fetal upper body, as is the case with oxygen and other endogenous substances. Studies were conducted with the histamine H1 antagonist, diphenhydramine (DPHM), in chronically instrumented nonpregnant and pregnant sheep (115-138 days gestation). Hepatic presystemic DPHM elimination was assessed using simultaneous and separate administration of DPHM and stable isotope labeled DPHM ([2H10]DPHM) via the umbilical vein (test route) and abdominal inferior vena cava (control route) in fetal lambs by either bolus injection (N = 6) or 90-min infusion (N = 5), and in nonpregnant sheep (N = 5), by simultaneous and separate bolus injections of the two forms of the drug via the mesenteric vein (test route) and abdominal inferior vena cava (control route). With the bolus injection protocol, hepatic presystemic elimination was estimated by the ratio of the area under the arterial drug concentration vs. time curve for the test and control routes of drug administration, whereas with the fetal infusion study it was calculated as the difference in fetal DPHM clearance values for the test and control routes of administration. To test for isotope effects in the disposition of [2H10]DPHM in the ewe or fetus, both DPHM and [2H10]DPHM were simultaneously injected via the inferior vena cava; however, no isotope effects were noted. In the ewe, there was extensive (93.2 +/- 1.4%) presystemic elimination of DPHM (F 0.068 +/- 0.014). However, in the fetus, this did not occur with bolus drug injection (F = 1.10 +/- 0.07), nor were there differences in the fetal DPHM clearance values estimated from the tarsal and umbilical venous infusions. During the latter experiments, DPHM levels were higher in the femoral artery than in carotid artery, with both umbilical venous and inferior vena caval drug infusion, and this was opposite of the differences in the concentrations of glucose, lactate, and oxygen between these two vessels. Thus, there is extensive hepatic presystemic elimination of DPHM in adult sheep, but no evidence for this phenomenon in the fetus. Furthermore, the preferential distribution of umbilical venous blood to the upper body of the fetal lamb does not result in higher drug levels in ascending aortic blood.
在本研究中,对两个可能影响胎儿药物暴露的因素进行了考察:1)经脐静脉从胎盘输送至胎儿肝脏的药物消除程度;2)脐静脉血中的药物向胎儿上半身优先分布的程度,这与氧气和其他内源性物质的情况相同。使用组胺H1拮抗剂苯海拉明(DPHM)对长期植入仪器的非孕和孕羊(妊娠115 - 138天)进行了研究。通过在胎羊中经脐静脉(测试途径)和腹下腔静脉(对照途径)推注给药(N = 6)或90分钟输注给药(N = 5),以及在非孕羊中经肠系膜静脉(测试途径)和腹下腔静脉(对照途径)同时分别推注两种形式的药物,来评估肝脏首过消除DPHM的情况。对于推注给药方案,通过测试和对照给药途径的动脉药物浓度 - 时间曲线下面积之比来估计肝脏首过消除情况,而对于胎儿输注研究,则计算测试和对照给药途径的胎儿DPHM清除率值之差。为了测试[2H10]DPHM在母羊或胎儿体内处置过程中的同位素效应,通过下腔静脉同时注射DPHM和[2H10]DPHM;然而,未观察到同位素效应。在母羊中,DPHM存在广泛的首过消除(93.2±1.4%)(F 0.068±0.014)。然而,在胎儿中,推注药物时并未出现这种情况(F = 1.10±0.07),从跗静脉和脐静脉输注估计的胎儿DPHM清除率值也没有差异。在后者的实验中,脐静脉和下腔静脉药物输注时,股动脉中的DPHM水平高于颈动脉,这与这两根血管之间葡萄糖、乳酸和氧气浓度的差异情况相反。因此,成年羊中存在广泛的肝脏首过消除DPHM的现象,但在胎儿中没有该现象的证据。此外,脐静脉血向胎羊上半身的优先分布并未导致升主动脉血中药物水平升高。